{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"groups":[{"description":"azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.\n\nlenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.","id":"OG000","title":"Lenalidomide and Azacitidine"}],"paramType":"NUMBER","populationDescription":"Intention to Treat","reportingStatus":"POSTED","timeFrame":"After 7 months","title":"Number of Patients That Experience Grade 3 or 4 Treatment Related Non-hematologic Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}